ENDRA Life Sciences Inc (NDRA) — Cash Flow-to-Debt Ratio
ENDRA Life Sciences Inc (NDRA) has a Cash Flow-to-Debt Ratio of -0.68x as of March 2026, meaning its operating cash flow of $-1.12 Million could theoretically repay -1% of its total liabilities ($1.65 Million) in one year. Check how aggressively does ENDRA Life Sciences Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ENDRA Life Sciences Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for ENDRA Life Sciences Inc across 12 annual periods. Also explore NDRA total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for ENDRA Life Sciences Inc (2014–2025)
Year-by-year debt coverage analysis for ENDRA Life Sciences Inc. For market capitalisation and broader financial context, see ENDRA Life Sciences Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.25x | $-5.18 Million | $1.59 Million | ▲ +16.9% |
| 2024 | -3.91x | $-7.40 Million | $1.89 Million | ▲ +55.1% |
| 2023 | -8.72x | $-9.55 Million | $1.10 Million | ▼ -41.3% |
| 2022 | -6.17x | $-12.77 Million | $2.07 Million | ▼ -16.0% |
| 2021 | -5.32x | $-11.12 Million | $2.09 Million | ▲ +21.2% |
| 2020 | -6.75x | $-10.77 Million | $1.60 Million | ▼ -89.8% |
| 2019 | -3.56x | $-8.59 Million | $2.42 Million | ▲ +55.0% |
| 2018 | -7.90x | $-7.70 Million | $974.58K | ▼ -103.1% |
| 2017 | -3.89x | $-3.30 Million | $848.21K | ▼ -309.5% |
| 2016 | -0.95x | $-1.32 Million | $1.38 Million | ▲ +73.3% |
| 2015 | -3.56x | $-842.73K | $236.42K | ▲ +75.1% |
| 2014 | -14.32x | $-1.40 Million | $97.60K | — |